SciClone Pharmaceuticals, Inc. Announces New ZADAXIN® Anti-Counterfeiting Label Wins Major Industry Award
Published: Dec 04, 2012
FOSTER CITY, CA--(Marketwire - December 04, 2012) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that its newly created anti-counterfeiting Pharma-Comb Void label for ZADAXIN has won the prestigious "Innovator Award" in the annual competition sponsored by the Tag and Label Manufacturers Institute (TLMI). The ZADAXIN label, which was created for SciClone by Schreiner MediPharm, a Germany-based developer and manufacturer of pharmaceutical specialty labels, is based on an innovative multi-part concept to ensure product safety and security and to counteract the illegal practice of refilling previously used medicine vials.
"Drug counterfeiting is a serious challenge facing the pharmaceutical industry, public health and regulatory authorities worldwide, threatening patient safety, compromising the supply and effectiveness of medical interventions and harming the commercial viability of important drug therapies," said Friedhelm Blobel, Ph.D., SciClone's Chief Executive Officer. "SciClone is committed to ensuring patient safety and security for all of our marketed products. We intend to continue implementation of an aggressive anti-counterfeiting strategy for ZADAXIN, and to work in partnership with agencies and health authorities to combat the crime of trafficking in illegal medicines."
The ZADAXIN Pharma-Comb Void label is designed to be functionally destroyed during its initial use. When the label's tear strip -- which also runs around the closure cap -- is removed, the inscriptions "Opened" and "Used" appear in the film's two indicator fields. This design is intended to make the undetected reuse of a glass container with an original label virtually impossible. SciClone believes that the Pharma-Comb Void label overcomes the limitations of conventional vial which, even when equipped with overt security features, such as holograms or color-shifting inks, can be filled a second time and sold as originals without detection. The new ZADAXIN label is designed to counteract this practice, and also offers a valuable added benefit for healthcare professionals: when the label is opened, a detachable part is released that serves to mark the syringe accordingly.
SciClone Pharmaceuticals is a US-based, China-focused specialty pharmaceutical company with a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Besides ZADAXIN, SciClone markets about 14 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit www.sciclone.com.
Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi and/or its affiliates.
Aggrastat is a registered trademark of Medicure International Inc. in the United States, and Iroko Cardio LLC in numerous other countries.
DC Bead is a registered trademark of Biocompatibles UK Limited.
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.
About Schreiner MediPharm
Based in the Munich area of Germany, Schreiner MediPharm is a global leader in the development and manufacture of innovative specialty labels with value-added benefits that have set the standard in the healthcare and pharmaceutical industries. Schreiner MediPharm's expertise is based on over 60 years of experience. The family-owned company provides specialty labels and label printing services to the biggest names in the healthcare market in over 20 countries around the world, including Japan. Schreiner MediPharm's U.S. facility, a business unit of Schreiner Group LP, is located in Blauvelt, NY. For additional information, please visit www.schreiner-medipharm.com.
Chief Financial Officer